21 May 2026
Shaily Engineering Plastics receives regulatory approval and launches a combination drug product incorporating its ShailyPen Neo device technology.
The wearable drug delivery segment is a high-barrier, high-value niche with growing global pharma outsourcing potential for contract device manufacturers.

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.